GlassScriptPhysician profile
Eleanor Wilkinson
NPI 1841821147
$5,270.48
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $825 · 2022: $1,823 · 2023: $1,670 · 2024: $953.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,622.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,537.97 | 2021-2024 | |
| Pfizer INC. | $348.83 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $300.20 | 2021-2024 | Austedo Xr |
| Sk Life Science, INC. | $270.33 | 2021-2024 | |
| Lilly USA, LLC | $255.25 | 2021-2024 | Amyvid, Emgality, Reyvow |
| Astrazeneca Pharmaceuticals LP | $250.87 | 2021-2023 | Andexxa |
| Amgen INC. | $240.88 | 2021-2023 | Aimovig |
| Lundbeck LLC | $198.48 | 2022-2024 | Vyepti |
| Otsuka America Pharmaceutical, INC. | $197.80 | 2023-2024 | Nuedexta, Rexulti |
| Ucb, INC. | $182.61 | 2022-2024 | Briviact, Rystiggo |
| Tanabe Pharma America, INC. | $155.84 | 2021-2024 | |
| Grifols USA, LLC | $140.59 | 2022-2023 | Gamunex-C |
| Amneal Pharmaceuticals LLC | $123.96 | 2021-2023 | Rytary |
| Biogen, INC. | $118.34 | 2021-2024 | Vumerity |
| Neurocrine Biosciences, INC. | $113.36 | 2022-2024 | Ingrezza, Ongentys |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $106.72 | 2023-2024 | |
| Argenx US, INC. | $81.83 | 2022-2023 | Vyvgart |
| Impel Pharmaceuticals INC. | $70.72 | 2022 | |
| Horizon Therapeutics Plc | $68.77 | 2022-2023 | Uplizna |
| Neurelis, INC. | $64.99 | 2022-2024 | Valtoco |
| Janssen Pharmaceuticals, INC | $60.17 | 2022 | |
| Emd Serono, INC. | $39.25 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $36.62 | 2022 | |
| Medtronic, INC. | $36.23 | 2023-2024 | Activa PC |
| Upsher-Smith Laboratories LLC | $33.07 | 2021 | |
| Averitas Pharma INC. | $26.14 | 2024 | Qutenza |
| Alnylam Pharmaceuticals INC. | $23.61 | 2021 | |
| Genzyme Corporation | $23.19 | 2022 | |
| Merz Pharmaceuticals, LLC | $23.09 | 2022 | |
| Adamas Pharmaceuticals, INC. | $21.70 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $20.24 | 2023 | Firdapse |
| Avion Pharmaceuticals | $20.17 | 2022 | |
| Eisai INC. | $18.67 | 2022 | |
| Scilex Pharmaceuticals INC. | $18.53 | 2023 | Ztlido |
| Tandem Diabetes Care, INC. | $15.69 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Alexion Pharmaceuticals, INC. | $14.69 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $11.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eleanor Wilkinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.